https://scholars.lib.ntu.edu.tw/handle/123456789/496049
標題: | Metformin use is associated with a lower risk of uterine leiomyoma in female type 2 diabetes patients | 作者: | CHIN-HSIAO TSENG | 關鍵字: | diabetes mellitus; metformin; Taiwan; uterine leiomyoma | 公開日期: | 2019 | 出版社: | SAGE Publications Ltd | 卷: | 10 | 來源出版物: | Therapeutic Advances in Endocrinology and Metabolism | 摘要: | Background: Whether metformin may reduce the risk of uterine leiomyoma in type 2 diabetes patients has not been investigated. This retrospective cohort study compared the risk of uterine leiomyoma in ever versus never users of metformin. Methods: Female patients with new-onset type 2 diabetes during 1999–2005 were enrolled from the reimbursement database of Taiwan’s National Health Insurance and followed up from 1 January 2006 until 31 December 2011. Analyses were conducted in a propensity score (PS) matched-pair cohort of 10,998 ever users and 10,998 never users of metformin. Hazard ratios were estimated by Cox regression incorporated with the inverse probability of treatment weighting using the PS. Results: A total of 321 never users and 162 ever users developed uterine leiomyoma during follow up, with respective incidence of 704.65 and 329.82 per 100,000 person-years. The overall hazard ratio was 0.467 (95% confidence interval: 0.387–0.564). The hazard ratios for the first (<23.3 months), second (23.3–53.1 months), and third (>53.1 months) tertiles of cumulative duration were 0.881 (0.685–1.132), 0.485 (0.367–0.642), and 0.198 (0.134–0.291), respectively; and were 0.751 (0.576–0.980), 0.477 (0.360–0.632), and 0.277 (0.198–0.386), respectively, for the first (<655,000 mg), second 655,000–1,725,500 mg), and third (>1,725,500) tertiles of cumulative dose. Sensitivity analyses after excluding users of sulfonylurea, users of estrogen, users of insulin, users of incretin-based therapies during follow up, patients with irregular drug refills, patients who discontinued the use of metformin, patients who received metformin prescription less than four times, or redefining uterine leiomyoma by using ‘diagnostic code’ plus ‘procedure codes’ consistently supported a lower risk of uterine leiomyoma in ever users of metformin. Conclusion: Metformin use is associated with a lower risk of uterine leiomyoma. ? The Author(s), 2019. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85077059959&doi=10.1177%2f2042018819895159&partnerID=40&md5=272c25514d0f251528401e1e8a1baa9c https://scholars.lib.ntu.edu.tw/handle/123456789/496049 |
ISSN: | 2042-0188 | DOI: | 10.1177/2042018819895159 | SDG/關鍵字: | acarbose; calcium channel blocking agent; estrogen; fibric acid derivative; hydroxymethylglutaryl coenzyme A reductase inhibitor; insulin; meglitinide; metformin; pioglitazone; rosiglitazone; sulfonylurea; adult; aged; Article; cancer risk; cohort analysis; disease duration; female; follow up; hazard ratio; human; major clinical study; non insulin dependent diabetes mellitus; Papanicolaou test; priority journal; propensity score; proportional hazards model; reimbursement; retrospective study; risk assessment; risk factor; sensitivity analysis; uterus myoma |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。